

Genetic Testing

Management across the universe of genetic testing

Genetic testing has changed dramatically and continues to evolve as additional delivery models and markets are explored. Due to the volume of orderable tests available, coding variability and increasingly complex medical policies, the effort required to manage genetic testing can seem endless. Despite accounting for 1-2% of medical spend, health plans can dedicate as much as 15% of clinical reviews and 20% of medical policies to this area.¹

Magellan Healthcare's innovative genetic testing solution, powered by Concert Genetics, focuses on authorization of testing services provided, rather than individual CPT codes, enabling health plans to unify efforts across utilization management, claims/payment integrity and provider network contracting in a tightly integrated manner for all genetic and molecular testing.



Expert-informed policies and guidelines—Machine-readable medical policies mapped to categories and domains of testing allow providers and health plan reviewers to easily identify relevant policies for each test.



Prior authorization—Medical necessity reviews for tests that are high-cost and have a high potential for misuse maximize program value.



Auto approval at intake—Robust clinical intake algorithms enable auto-approval for requests meeting medical necessity criteria to reduce administrative burden and provider abrasion.



Specialty-trained staff—Magellan board-certified clinical geneticists and specialty-matched physicians trained extensively in genetic and molecular testing services review pended cases to ensure medical necessity and clinical appropriateness.



Pre-payment, post-service claim edits—Payment integrity and clinical claim edits provide plans with fundamental controls for improving oversight of laboratories and are applied to low-cost, high-volume tests.



Proprietary technology platform—Using artificial intelligence, all tests are automatically and continuously monitored and reviewed against medical guidelines, price benchmarks and correct codes.

With genetic testing growing at an estimated 13% annually² and spending projected to reach \$10.3 billion by 2027³, the unique challenges of genetic testing will continue. Contact us at mhinfo@magellanhealth.com to learn how Magellan's genetic testing solution can help manage variation and risk while reducing administrative burden and medical costs.

1. Concert Genetics Analysis, 2020

2. Fortune Business Insights, 2021

3. Fortune Business Insights, 2021